# Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

> **NCT02513472** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 258 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Eribulin Mesylate
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02513472
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-28
- **Primary completion:** 2019-07-31
- **Final completion:** 2021-04-06
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2022-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02513472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02513472, "Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02513472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*